Results 11 to 20 of about 11,407 (242)

Biosimilars in Oncology: Latest Trends and Regulatory Status [PDF]

, 2022
Biologic-based medicines are used to treat a variety of diseases and account for around one-quarter of the worldwide pharmaceutical market. The use of biologic medications among cancer patients has resulted in substantial advancements in cancer treatment
Sukriti Vishwas, Thakur Gurjeet Singh, Saurabh Gupta, Sharma, Sumit, Rubiya Khursheed, Williams, Kylie A., Dua, Kamal, Goyal, S, Sumit Sharma, Singh, TG, Gauniyal, S, Khursheed, R, Porwal, Sejal, Wadhwa, Diksha, Joshi, D, Eri, RD, Khursheed, Rubiya, Porwal, S, Gupta, Saurabh, Gaurav Gupta, Sanjay Goyal, Dua, K, Vishwas, Sukriti, Goyal, Sanjay, Kylie A. Williams, Singh, Thakur Gurjeet, Sejal Porwal, Singh, Sachin Kumar, Gupta, S, Wadhwa, D, Joshi, Deeksha, Singh, SK, Gauniyal, Swati, Williams, KA, Deeksha Joshi, Diksha Wadhwa, Gupta, Gaurav, Rajaraman D. Eri, Vishwas, S, Swati Gauniyal, Eri, Rajaraman D., Sachin Kumar Singh, Sharma, S, Gupta, G, Kamal Dua   +44 more
core   +1 more source

Pharmacists' confidence in explaining biosimilars to patients before a nationwide medicine change: A cross-sectional study

Exploratory Research in Clinical and Social Pharmacy, 2022
Background: Biosimilars can improve patient access to biological medicines. Although biosimilars have been shown to be equally effective and safe, some patients remain reluctant to transition to biosimilars.
Chiara Gasteiger, Norina Gasteiger, Keith J. Petrie   +2 more
doaj   +1 more source

Biosimilar insulins in international and domestic practice of pharmacist

Фармацевтичний журнал, 2022
In Ukraine, people with diabetes receive insulin, including insulin biosimilars in pharmacies, so pharmacists should increase their knowledge about biosimilar because they become more available in the coming years. The aim of the work was to summarize
I. O. Vlasenko, I. V. Nizhenkovska
doaj   +1 more source

Biosimilars [PDF]

, 2022
Introduced in the 1980s, biologic medications have since become important tools in modern medicine. However, biologics are expensive, greatly affecting the healthcare budgets of both underdeveloped and developed countries. Fortunately, biosimilars, which

core   +1 more source

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis

Arthritis Research & Therapy, 2020
Background ABP 710 is being developed as a biosimilar to infliximab reference product (RP). Analytical similarity and pharmacokinetic equivalence between the two have been previously demonstrated.
Mark C. Genovese, Juan Sanchez-Burson, MyungShin Oh, Eva Balazs, Jeffrey Neal, Andrea Everding, Tomas Hala, Rafal Wojciechowski, Gary Fanjiang, Stanley Cohen   +9 more
doaj   +1 more source

Biosimilar knowledge and viewpoints among Brazilian inflammatory bowel disease patients

Therapeutic Advances in Gastroenterology, 2021
Background: In this analysis we aimed to describe Brazilian inflammatory bowel disease (IBD) patients’ knowledge and perceptions regarding biosimilars and compare with viewpoints from non-Brazilian patients.
Karoline Soares Garcia, Bianca Pocopetz Facas, Marta Brenner Machado, Fábio Vieira Teixeira, Luisa Avedano, Sanna Lönnfors, Rogério Saad Hossne, Laurent Peyrin-Biroulet, Natália Sousa Freitas Queiroz   +8 more
doaj   +1 more source

Knowledge, Attitudes and Practice of Healthcare Providers, Healthcare Regulatory Practitioners and Patients Toward Biosimilars in China: Insights From a Nationwide Survey

Frontiers in Pharmacology, 2022
Objective: With increasing numbers of biosimilars entering the market or in the approval pipeline in China, understanding the current awareness and attitudes of biosimilars still remains the first step to promote uptake.
Yang Hu, Yang Hu, Yang Hu, Yang Hu, Zaiwei Song, Zaiwei Song, Zaiwei Song, Dan Jiang, Dan Jiang, Dan Jiang, Dan Jiang, Lin Zhuo, Yinchu Cheng, Yinchu Cheng, Yinchu Cheng, Rongsheng Zhao, Rongsheng Zhao, Rongsheng Zhao   +17 more
doaj   +1 more source

Biosimilars [PDF]

Therapeutische Umschau, 2011
Die Bewertung von Biosimilars stellt eine Herausforderung für alle an der Zulassung und an der Arzneimittelauswahl Beteiligten im Gesundheitswesen dar. Bewertungskriterien sind wie bei allen Arzneimitteln Qualität, Wirksamkeit, Sicherheit/Verträglichkeit und Wirtschaftlichkeit.
openaire   +6 more sources

Potential Cost-Savings From the Use of the Biosimilars in Slovakia

Frontiers in Public Health, 2020
Objectives: To analyse the market shares of biosimilars in Slovakia and to calculate the potential cost-savings from the use of biosimilars in Slovakia based on two different data sources.Methods: National reimbursement lists from the Czech Republic ...
Tomas Tesar, Peter Golias, Zuzana Kobliskova, Martin Wawruch, Paweł Kawalec, András Inotai, András Inotai   +6 more
doaj   +1 more source

Budget Impact Analysis of Biosimilar Products in Spain in the Period 2009–2019

Pharmaceuticals, 2021
Since the first biosimilar medicine, Omnitrope® (active substance somatropin) was approved in 2006, 53 biosimilars have been authorized in Spain. We estimate the budget impact of biosimilars in Spain from the perspective of the National Health System ...
Manuel García-Goñi, Isabel Río-Álvarez, David Carcedo, Alba Villacampa   +3 more
doaj   +1 more source